150 related articles for article (PubMed ID: 35775579)
1. Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.
O'Malley T; Xie F; Su Y; Clinton C; Zack DJ; Haechung C; Grabner M; Curtis JR
J Manag Care Spec Pharm; 2022 Sep; 28(9):1021-1032. PubMed ID: 35775579
[No Abstract] [Full Text] [Related]
2. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
[No Abstract] [Full Text] [Related]
3. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.
Wu SS; Perry A; Tkacz J; Bryant G
J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115
[No Abstract] [Full Text] [Related]
4. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.
Mossell J; Goldman JA; Barken D; Alexander RV
Open Rheumatol J; 2016; 10():71-80. PubMed ID: 27867431
[TBL] [Abstract][Full Text] [Related]
5. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression.
Liang E; Taylor M; McMahon M
Lupus Sci Med; 2020; 7(1):e000345. PubMed ID: 32231785
[TBL] [Abstract][Full Text] [Related]
6. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.
Alexander RV; Rey DS; Conklin J; Domingues V; Ahmed M; Qureshi J; Weinstein A
Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253650
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
Lokhandwala T; Coutinho AD; Bell CF
Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
9. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
10. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
11. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States.
Murimi-Worstell IB; Lin DH; Kan H; Tierce J; Wang X; Nab H; Desta B; Alexander GC; Hammond ER
J Rheumatol; 2021 Mar; 48(3):385-393. PubMed ID: 32611669
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States.
Pizzicato LN; Vadhariya A; Birt J; Ketkar AG; Bolce R; Grabner M; Pepe RS; Walsh JA
J Manag Care Spec Pharm; 2023 Jan; 29(1):24-35. PubMed ID: 36318701
[No Abstract] [Full Text] [Related]
13. Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes Care.
Bieszk N; Grabner M; Wei W; Barron J; Quimbo R; Yan T; Biel B; Chu JW
J Manag Care Spec Pharm; 2017 Nov; 23(11):1160-1168. PubMed ID: 29083969
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
Bell CF; Ajmera MR; Meyers J
Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
[TBL] [Abstract][Full Text] [Related]
15. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population.
Chung H; Crowe CL; Kong SX; Singh R; Farej R; Elliott J; Williamson T; Willey VJ
J Manag Care Spec Pharm; 2023 Jan; 29(1):80-89. PubMed ID: 36580126
[No Abstract] [Full Text] [Related]
16. A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.
Ke X; Eisenberg Lawrence DF; Oglesby A; Patel J; Kan H; Boggs R
Clin Ther; 2015 Dec; 37(12):2852-63. PubMed ID: 26547483
[TBL] [Abstract][Full Text] [Related]
17. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
Kariburyo F; Xie L; Sah J; Li N; Lofland JH
J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
[No Abstract] [Full Text] [Related]
18. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
[TBL] [Abstract][Full Text] [Related]
19. Differences in the diagnosis and management of systemic lupus erythematosus by primary care and specialist providers in the American Indian/Alaska Native population.
McDougall JA; Helmick CG; Lim SS; Johnston JM; Gaddy JR; Gordon C; Ferucci ED
Lupus; 2018 Jun; 27(7):1169-1176. PubMed ID: 29554837
[TBL] [Abstract][Full Text] [Related]
20. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]